<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056496</url>
  </required_header>
  <id_info>
    <org_study_id>CEBAS-CSIC-3</org_study_id>
    <nct_id>NCT02056496</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Urolithins in Healthy Subjects.</brief_title>
  <acronym>POMEkinetics</acronym>
  <official_title>Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Gut Microbiota-derived Metabolites (Urolithins) in Overweight Subjects. Comparison Between Two Pomegranate Extracts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Council, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Católica San Antonio de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Council, Spain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pomegranate phenolics (such as the ellagitannin punicalagin and ellagic acid) are metabolized
      by the human gut microbiota to yield a number of metabolites called urolithins (mainly
      Uro-A). Both ellagic acid (EA) and urolithins can exert a number of biological activities.
      However, the bioavailability of ellagic acid has been reported to be very low and the
      existing studies are controversial so far. The investigators want to carry out a robust
      (cross-over, double-blind) pharmacokinetic assay in 20 healthy volunteers, using two types of
      pomegranate extracts (PEs). PEs with low (PE-1) and high (PE-2) punicalagin:EA ratio will be
      administered. The investigators will analyze blood and urine samples using
      UPLC-ESI-QTOF-MS/MS. The investigators will evaluate:

        -  The pharmacokinetics of EA.

        -  The effect of punicalagin:free EA ratio on the pharmacokinetics of EA and urolithins
           production.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour pharmacokinetics of ellagic acid in plasma</measure>
    <time_frame>Outcome measures at 0.5, 1, 2, 3, 4, 5, 6, and 24 hours post‐dose.</time_frame>
    <description>Determination of pharmacokinetic parameters (Cmax, Tmax, AUC, etc.) for ellagic acid and derived metabolites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>72-h accumulation of urolithins in urine</measure>
    <time_frame>Changes from baseline at 24, 48 and 72 hours</time_frame>
    <description>Production of urolithins depending on the punicalagin:free ellagic acid ratio.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The same group will consume the two types of pomegranate extract (crossover study).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract</intervention_name>
    <description>Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).</description>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <other_name>PE-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pomegranate extract</intervention_name>
    <description>Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).</description>
    <arm_group_label>Pomegranate extract</arm_group_label>
    <other_name>PE-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-35 years.

          -  Healthy status (no illness in the previous 3-months).

        Exclusion Criteria:

          -  Smoking.

          -  Pregnancy/lactation.

          -  Severe medical illness/chronic disease/ or gastrointestinal pathology (ulcers,
             irritable bowel syndrome, ulcerative colitis, Crohn disease etc.).

          -  Previous gastrointestinal surgery

          -  Recent use of antibiotics (within 1-month prior to the study)

          -  Suspected hypersensitivity to pomegranate or any of its components

          -  Consumption of nutraceuticals, botanical extracts or other vitamin supplements or
             taking medication.

          -  Regular consumption of ellagitannin-containing foodstuffs (walnuts, pomegranate,
             strawberries, raspberries, oak-aged red wine) (after filling a food-frequency
             questionnaire).

          -  Intake of ellagitannins-containing foodstuffs the week before the pharmacokinetic
             intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Juan Carlos Espín, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Council (CEBAS-CSIC, Murcia, Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCAM (San Antonio Catholic University from Murcia)</name>
      <address>
        <city>Murcia</city>
        <zip>30107</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Council, Spain</investigator_affiliation>
    <investigator_full_name>Juan Carlos Espín de Gea</investigator_full_name>
    <investigator_title>Full Research Professor</investigator_title>
  </responsible_party>
  <keyword>Pomegranate</keyword>
  <keyword>Ellagic acid</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Urolithins</keyword>
  <keyword>Bioavailability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

